Sylvarum develops and deploys non-thermal (cold) plasma seed treatments that aim to improve germination, reduce pathogens, and revitalize seeds without chemical residues. Their technology has been validated in trials reporting a 60% reduction in seed latency, an active treatment window of six to eight months, and estimated savings of about US$800,000 per processing plant, with broader industry citations of roughly 10% production recovery. The core team and technology trace to academic research led by Dr. Karina Balestrasse (FAUBA/CONICET) and Dr. Leandro Prevosto with over 15 years of research experience. Sylvarum’s business model sells the treatment as an integrated service to seed companies rather than as standalone equipment, creating recurring revenue potential and lower adoption barriers. Financially, the company recently raised US$850,000 from national and international investment funds, including Inventure and the Aapresid fund. The company positions itself against conventional chemical treatments and other physical seed-conditioning methods by emphasizing a science-backed, chemical-free process that integrates into existing processing plants.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

May 2026